Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DCTH Delcath Systems	$12.55 +1.1%	$14.77	$7.17 ▼ $18.23	$432.19M	0.87	429,123 shs	486,164 shs
EYE National Vision	$24.54 -2.8%	$20.65	$9.56 ▼ $25.39	$2.00B	1.27	1.92 million shs	2.15 million shs
LMAT LeMaitre Vascular	$85.75 +1.4%	$82.62	$71.42 ▼ $109.58	$1.91B	0.82	170,107 shs	113,383 shs
NVCR NovoCure	$18.46 +1.5%	$17.67	$14.17 ▼ $34.13	$2.03B	0.72	1.13 million shs	652,317 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DCTH Delcath Systems	+1.13%	-1.38%	-22.58%	+17.73%	+54.18%
EYE National Vision	-2.81%	+2.70%	+16.75%	+112.65%	+102.48%
LMAT LeMaitre Vascular	+1.42%	+1.59%	+2.53%	+3.54%	+2.78%
NVCR NovoCure	+1.48%	+4.26%	+0.44%	+11.88%	+9.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DCTH Delcath Systems	3.2529 of 5 stars	3.5	5.0	0.0	0.0	1.1	2.5	0.6
EYE National Vision	2.6625 of 5 stars	2.3	2.0	0.0	3.3	2.1	0.8	0.0
LMAT LeMaitre Vascular	2.5617 of 5 stars	2.2	1.0	3.3	0.0	2.1	2.5	1.3
NVCR NovoCure	3.604 of 5 stars	3.4	1.0	0.0	4.5	1.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DCTH Delcath Systems	3.00	Buy	$24.00	91.24% Upside
EYE National Vision	2.56	Moderate Buy	$22.10	-9.94% Downside
LMAT LeMaitre Vascular	2.33	Hold	$97.83	14.09% Upside
NVCR NovoCure	2.71	Moderate Buy	$32.43	75.67% Upside

Current Analyst Ratings Breakdown

Latest DCTH, NVCR, LMAT, and EYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	EYE National Vision	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/8/2025	EYE National Vision	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$30.00
7/8/2025	EYE National Vision	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$17.00 ➝ $30.00
7/8/2025	NVCR NovoCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/27/2025	NVCR NovoCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$34.00
6/23/2025	DCTH Delcath Systems	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00
6/18/2025	EYE National Vision	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $26.00
5/23/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $29.00
5/19/2025	EYE National Vision	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Perform ➝ Market Perform	$13.00 ➝ $19.00
5/12/2025	EYE National Vision	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $17.00
5/9/2025	EYE National Vision	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$13.00 ➝ $17.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DCTH Delcath Systems	$37.21M	11.75	N/A	N/A	$2.15 per share	5.84
EYE National Vision	$1.82B	1.06	$1.59 per share	15.44	$10.37 per share	2.37
LMAT LeMaitre Vascular	$226.26M	8.56	$2.42 per share	35.40	$15.00 per share	5.72
NVCR NovoCure	$605.22M	3.40	N/A	N/A	$3.33 per share	5.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DCTH Delcath Systems	-$26.39M	-$0.50	N/A	N/A	N/A	-26.38%	-29.44%	-20.75%	8/4/2025 (Estimated)
EYE National Vision	-$28.50M	-$0.33	N/A	90.89	3.70	-1.40%	3.44%	1.40%	8/6/2025 (Estimated)
LMAT LeMaitre Vascular	$44.04M	$1.98	43.31	39.52	2.23	19.96%	13.53%	9.78%	8/5/2025 (Estimated)
NVCR NovoCure	-$168.63M	-$1.51	N/A	N/A	N/A	-26.41%	-45.46%	-13.34%	7/24/2025 (Estimated)

Latest DCTH, NVCR, LMAT, and EYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	EYE National Vision	$0.12	N/A	N/A	N/A	$469.21 million	N/A
8/5/2025	Q2 2025	LMAT LeMaitre Vascular	$0.57	N/A	N/A	N/A	$62.48 million	N/A
8/4/2025	Q2 2025	DCTH Delcath Systems	$0.02	N/A	N/A	N/A	$22.84 million	N/A
7/24/2025	Q2 2025	NVCR NovoCure	-$0.40	N/A	N/A	N/A	$153.87 million	N/A
5/8/2025	Q1 2025	DCTH Delcath Systems	$0.10	$0.03	-$0.07	$0.03	$16.83 million	$19.80 million
5/7/2025	Q1 2025	EYE National Vision	$0.32	$0.34	+$0.02	$0.18	$510.30 million	$510.32 million
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
EYE National Vision	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.93%	N/A	40.40%	14 Years
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A

Latest DCTH, NVCR, LMAT, and EYE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DCTH Delcath Systems	N/A	15.95	14.61
EYE National Vision	0.29	0.54	0.35
LMAT LeMaitre Vascular	0.48	16.49	13.83
NVCR NovoCure	0.27	1.47	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DCTH Delcath Systems	61.12%
EYE National Vision	N/A
LMAT LeMaitre Vascular	84.64%
NVCR NovoCure	84.61%

Insider Ownership

Company	Insider Ownership
DCTH Delcath Systems	17.40%
EYE National Vision	2.70%
LMAT LeMaitre Vascular	9.50%
NVCR NovoCure	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DCTH Delcath Systems	60	34.83 million	28.77 million	Optionable
EYE National Vision	13,411	79.05 million	76.92 million	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.45 million	Optionable
NVCR NovoCure	1,488	111.49 million	105.33 million	Optionable

DCTH, NVCR, LMAT, and EYE Headlines

Recent News About These Companies

NovoCure (NASDAQ:NVCR) Research Coverage Started at LADENBURG THALM/SH SH

4 hours ago | americanbankingnews.com

Ladenburg Thalmann Initiates Coverage of NovoCure (NVCR) with Buy Recommendation

July 9 at 3:55 AM | msn.com

NovoCure (NASDAQ:NVCR) Coverage Initiated at LADENBURG THALM/SH SH

July 8 at 8:40 AM | marketbeat.com

Summit Trail Advisors LLC Acquires 40,570 Shares of NovoCure Limited (NASDAQ:NVCR)

July 2, 2025 | marketbeat.com

Brokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $32.83

July 2, 2025 | americanbankingnews.com

Strong week for NovoCure (NASDAQ:NVCR) shareholders doesn't alleviate pain of three-year loss

June 30, 2025 | finance.yahoo.com

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

June 30, 2025 | zacks.com

NovoCure Limited (NASDAQ:NVCR) Shares Sold by Taylor Frigon Capital Management LLC

June 30, 2025 | marketbeat.com

Novocure to Report Second Quarter 2025 Financial Results

June 30, 2025 | businesswire.com

NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by Analysts

June 29, 2025 | marketbeat.com

Demystifying NovoCure: Insights From 4 Analyst Reviews

June 27, 2025 | benzinga.com

NovoCure's (NVCR) "Overweight" Rating Reiterated at Piper Sandler

June 27, 2025 | marketbeat.com

SG Americas Securities LLC Invests $527,000 in NovoCure Limited (NASDAQ:NVCR)

June 23, 2025 | marketbeat.com

NovoCure (NASDAQ:NVCR) Shares Down 3.4% - What's Next?

June 18, 2025 | marketbeat.com

What Makes NovoCure (NVCR) a New Buy Stock

June 18, 2025 | zacks.com

GAMMA Investing LLC Purchases 47,152 Shares of NovoCure Limited (NASDAQ:NVCR)

June 17, 2025 | marketbeat.com

Simon Quick Advisors LLC Takes Position in NovoCure Limited (NASDAQ:NVCR)

June 16, 2025 | marketbeat.com

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial

June 6, 2025 | zacks.com

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

June 2, 2025 | businesswire.com

Novocure data support pancreatic cancer approval, says Wells Fargo

June 2, 2025 | msn.com

Novocure study shows improved pancreatic cancer survival

June 2, 2025 | massdevice.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH, NVCR, LMAT, and EYE Company Descriptions

Delcath Systems NASDAQ:DCTH

$12.55 +0.14 (+1.13%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$12.52 -0.03 (-0.20%)

As of 04:51 AM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

National Vision NASDAQ:EYE

$24.54 -0.71 (-2.81%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$24.54 0.00 (0.00%)

As of 07/10/2025 07:35 PM Eastern

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

LeMaitre Vascular NASDAQ:LMAT

$85.75 +1.20 (+1.42%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$85.75 0.00 (0.00%)

As of 07/10/2025 06:12 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NovoCure NASDAQ:NVCR

$18.46 +0.27 (+1.48%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$18.42 -0.04 (-0.22%)

As of 07/10/2025 07:51 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time